Article info
PDFClinical and epidemiological research
Concise report
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
- Correspondence to Dr M C Genovese, Division of Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA; genovese{at}stanford.edu
Citation
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
Publication history
- Accepted December 14, 2008
- First published January 20, 2009.
Online issue publication
October 31, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/